Wellington Management Group LLP Biotechnology

Wellington Management Group LLP

$557 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$102B	$2.23 Billion 0.4% of portfolio	4,798,870	Q3 2024 Added 17.2%
ALNY Alnylam Pharmaceuticals, Inc.	$30.2B	$1.36 Billion 0.24% of portfolio	4,953,347	Q3 2024 Reduced 20.24%
UTHR United Therapeutics Corp	$16.4B	$1.14 Billion 0.2% of portfolio	3,170,849	Q3 2024 Reduced 3.48%
RVMD Revolution Medicines, Inc.	$3.86B	$517 Million 0.09% of portfolio	11,401,394	Q3 2024 Reduced 16.54%
PCVX Vaxcyte, Inc.	$5.13B	$515 Million 0.09% of portfolio	4,513,756	Q3 2024 Reduced 1.73%
REGN Regeneron Pharmaceuticals, Inc.	$75.2B	$463 Million 0.08% of portfolio	440,609	Q3 2024 Reduced 58.5%
APLS Apellis Pharmaceuticals, Inc.	$3.65B	$449 Million 0.08% of portfolio	15,566,969	Q3 2024 Reduced 5.01%
CYTK Cytokinetics Inc	$4.6B	$411 Million 0.07% of portfolio	7,774,970	Q3 2024 Added 3.53%
BPMC Blueprint Medicines Corp	$5.38B	$367 Million 0.07% of portfolio	3,964,610	Q3 2024 Added 22.53%
IONS Ionis Pharmaceuticals Inc	$5.06B	$350 Million 0.06% of portfolio	8,735,787	Q3 2024 Added 32.99%
MRNA Moderna, Inc.	$15.4B	$349 Million 0.06% of portfolio	5,224,685	Q3 2024 Added 20.98%
SRPT Sarepta Therapeutics, Inc.	$10.4B	$341 Million 0.06% of portfolio	2,726,613	Q3 2024 Added 32.26%
RNA Avidity Biosciences, Inc.	$1.66B	$323 Million 0.06% of portfolio	7,030,949	Q3 2024 Added 84.93%
CLDX Celldex Therapeutics, Inc.	$1.18B	$314 Million 0.06% of portfolio	9,243,599	Q3 2024 Added 14.46%
DNLI Denali Therapeutics Inc.	$2.88B	$312 Million 0.06% of portfolio	10,727,450	Q3 2024 Added 9.2%
PTCT Ptc Therapeutics, Inc.	$3.31B	$293 Million 0.05% of portfolio	7,892,799	Q3 2024 Reduced 3.85%
ARGX Argenx Se	$34.5B	$262 Million 0.05% of portfolio	482,346	Q3 2024 Added 13.03%
FOLD Amicus Therapeutics, Inc.	$2.75B	$256 Million 0.05% of portfolio	23,964,044	Q3 2024 Added 13.53%
RARE Ultragenyx Pharmaceutical Inc.	$3.1B	$231 Million 0.04% of portfolio	4,165,424	Q3 2024 Reduced 8.58%
CRNX Crinetics Pharmaceuticals, Inc.	$2.88B	$228 Million 0.04% of portfolio	4,459,691	Q3 2024 Reduced 3.48%
AKRO Akero Therapeutics, Inc.	$1.36B	$227 Million 0.04% of portfolio	7,896,632	Q3 2024 Added 54.39%
IMCR Immunocore Holdings PLC	$1.24B	$219 Million 0.04% of portfolio	7,048,833	Q3 2024 Added 10.48%
KYMR Kymera Therapeutics, Inc.	$2.22B	$219 Million 0.04% of portfolio	4,618,359	Q3 2024 Added 7.17%
RCKT Rocket Pharmaceuticals, Inc.	$875M	$208 Million 0.04% of portfolio	11,242,144	Q3 2024 Added 22.79%
ZLAB Zai Lab LTD	$2.62B	$204 Million 0.04% of portfolio	8,436,606	Q3 2024 Added 18.42%
ASND Ascendis Pharma A/S	$7.61B	$188 Million 0.03% of portfolio	1,261,480	Q3 2024 Reduced 51.72%
XENE Xenon Pharmaceuticals Inc.	$2.41B	$151 Million 0.03% of portfolio	3,843,447	Q3 2024 Added 0.4%
MRUS Merus N.V.	$1.92B	$144 Million 0.03% of portfolio	2,887,514	Q3 2024 Added 73.64%
VCYT Veracyte, Inc.	$2.93B	$144 Million 0.03% of portfolio	4,232,844	Q3 2024 Reduced 38.44%
TECH Bio Techne Corp	$2.87B	$122 Million 0.02% of portfolio	1,532,589	Q3 2024 Reduced 8.8%
IMTX Immatics N.V.	$522M	$110 Million 0.02% of portfolio	9,681,183	Q3 2024 Added 1.52%
NUVL Nuvalent, Inc.	$3.62B	$104 Million 0.02% of portfolio	1,011,837	Q3 2024 Added 65.49%
LEGN Legend Biotech Corp	$5.71B	$99.2 Million 0.02% of portfolio	2,036,370	Q3 2024 Reduced 27.52%
SNDX Syndax Pharmaceuticals Inc	$740M	$96 Million 0.02% of portfolio	4,985,976	Q3 2024 Reduced 32.06%
AUTL Autolus Therapeutics PLC	$208M	$87.9 Million 0.02% of portfolio	24,220,226	Q3 2024 Added 35.39%
NRIX Nurix Therapeutics, Inc.	$935M	$78.2 Million 0.01% of portfolio	3,482,105	Q3 2024 Added 8.75%
INSM Insmed Inc	$9.54B	$70.3 Million 0.01% of portfolio	962,459	Q3 2024 Added 2.56%
PRTA Prothena Corp Public LTD CO	$714M	$69.9 Million 0.01% of portfolio	4,178,788	Q3 2024 Added 14.82%
AXSM Axsome Therapeutics, Inc.	$3.89B	$66.7 Million 0.01% of portfolio	742,745	Q3 2024 Added 1.11%
GERN Geron Corp	$1.32B	$57.5 Million 0.01% of portfolio	12,662,404	Q3 2024 Added 4.72%
GMAB Genmab A/S	$13.4B	$56.2 Million 0.01% of portfolio	2,306,250	Q3 2024 Reduced 0.03%
VRNA Verona Pharma PLC	$2.56B	$54 Million 0.01% of portfolio	1,878,632	Q3 2024 Added 19.55%
LBPH Longboard Pharmaceuticals, Inc.	$815M	$53 Million 0.01% of portfolio	1,590,072	Q3 2024 Reduced 10.62%
NVO Novo Nordisk A S	$192B	$42 Million 0.01% of portfolio	352,878	Q3 2024 New
SVRA Savara Inc	$368M	$36.6 Million 0.01% of portfolio	8,624,012	Q3 2024 Added 22.93%
VCEL Vericel Corp	$2.67B	$24.8 Million 0.0% of portfolio	587,857	Q3 2024 Added 214.04%
TRDA Entrada Therapeutics, Inc.	$552M	$16.5 Million 0.0% of portfolio	1,029,369	Q3 2024 Reduced 0.44%
NTLA Intellia Therapeutics, Inc.	$926M	$13.2 Million 0.0% of portfolio	644,763	Q3 2024 Reduced 17.53%
OLMA Olema Pharmaceuticals, Inc.	$247M	$12 Million 0.0% of portfolio	1,002,685	Q3 2024 Added 10.76%
DAWN Day One Biopharmaceuticals, Inc.	$940M	$10.1 Million 0.0% of portfolio	721,581	Q3 2024 Added 142.11%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.